| Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, ... Blood advances 4 (22), 5607-5615, 2020 | 311 | 2020 |
| PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance B Tessoulin, G Descamps, P Moreau, S Maïga, L Lodé, C Godon, ... Blood, The Journal of the American Society of Hematology 124 (10), 1626-1636, 2014 | 167 | 2014 |
| Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial S Le Gouill, F Morschhauser, D Chiron, K Bouabdallah, G Cartron, ... Blood, The Journal of the American Society of Hematology 137 (7), 877-887, 2021 | 113 | 2021 |
| Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma D Chiron, C Bellanger, A Papin, B Tessoulin, C Dousset, S Maiga, ... Blood, The Journal of the American Society of Hematology 128 (24), 2808-2818, 2016 | 90 | 2016 |
| Long‐term outcome of monoclonal (type 1) cryoglobulinemia A Néel, F Perrin, O Decaux, T Dejoie, B Tessoulin, M Halliez, B Mahé, ... American journal of hematology 89 (2), 156-161, 2014 | 85 | 2014 |
| Description of neurotoxicity in a series of patients treated with CAR T-cell therapy C Belin, P Devic, X Ayrignac, A Dos Santos, A Paix, L Sirven-Villaros, ... Scientific Reports 10 (1), 18997, 2020 | 81 | 2020 |
| Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review A Néel, A Wahbi, B Tessoulin, J Boileau, D Carpentier, O Decaux, ... Critical Care 22, 1-10, 2018 | 77 | 2018 |
| Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT B Tessoulin, J Delaunay, P Chevallier, M Loirat, S Ayari, P Peterlin, ... Bone marrow transplantation 49 (4), 567-571, 2014 | 72 | 2014 |
| BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker B Tessoulin, A Papin, P Gomez-Bougie, C Bellanger, M Amiot, ... Frontiers in oncology 8, 645, 2019 | 71 | 2019 |
| Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study BJ Gaborit, B Tessoulin, RA Lavergne, F Morio, C Sagan, E Canet, ... Annals of intensive care 9, 1-10, 2019 | 68 | 2019 |
| BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment P Gomez-Bougie, S Maiga, B Tessoulin, J Bourcier, A Bonnet, ... Blood, The Journal of the American Society of Hematology 132 (25), 2656-2669, 2018 | 68 | 2018 |
| Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study É Azoulay, P Castro, A Maamar, V Metaxa, AG De Moraes, L Voigt, ... The Lancet Haematology 8 (5), e355-e364, 2021 | 61 | 2021 |
| CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages A Papin, B Tessoulin, C Bellanger, A Moreau, Y Le Bris, H Maisonneuve, ... Leukemia 33 (10), 2442-2453, 2019 | 59 | 2019 |
| Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study E Iannitto, M Bellei, S Amorim, AJM Ferreri, L Marcheselli, M Cesaretti, ... British journal of haematology 183 (5), 755-765, 2018 | 57 | 2018 |
| p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell B Tessoulin, M Eveillard, A Lok, D Chiron, P Moreau, M Amiot, ... Blood Reviews 31 (4), 251-259, 2017 | 56 | 2017 |
| Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single … A Lassalle, P Thomaré, C Fronteau, B Mahé, C Jubé, N Blin, M Voldoire, ... Annals of Oncology 27 (2), 314-318, 2016 | 45 | 2016 |
| Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma ML Wang, W Jurczak, PL Zinzani, TA Eyre, CY Cheah, CS Ujjani, Y Koh, ... Journal of Clinical Oncology 41 (24), 3988-3997, 2023 | 42 | 2023 |
| Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways B Tessoulin, A Moreau-Aubry, G Descamps, P Gomez-Bougie, S Maïga, ... Journal of hematology & oncology 11, 1-13, 2018 | 40 | 2018 |
| Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study M Jullien, S Trudel, B Tessoulin, B Mahé, V Dubruille, N Blin, T Gastinne, ... Annals of Hematology 98, 1435-1440, 2019 | 38 | 2019 |
| Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC B Tessoulin, P Ceballos, P Chevallier, D Blaise, O Tournilhac, J Gauthier, ... Bone marrow transplantation 51 (9), 1184-1190, 2016 | 37 | 2016 |
Catherine Pellat-DeceunynckCRCINA INSERM 1232 CNRS 6001在 inserm.fr 的电子邮件经过验证
